Results 131 to 140 of about 168,705 (262)

Departing from standard practices: Strategic application of value engineering in the anatomy laboratory to enhance formaldehyde extraction using high‐impact, low‐cost, and low‐maintenance solutions

Anatomical Sciences Education, Volume 18, Issue 3, Page 241-253, March 2025.
Abstract This study describes the process of developing a high‐impact, low‐cost, and low‐maintenance air ventilation system for anatomy facilities. It employed the strategic application of Value Engineering (VE), assuring that the air ventilation system meets contemporary threshold limit values (TLVs) for formaldehyde in the working zone of dissection ...
Jürgen Russ, Niels Hammer
wiley   +1 more source

Beijing's ART insurance coverage: enhancing outpatient visit frequency and reducing out-of-pocket costs. [PDF]

BMC Health Serv Res
Wang C, Fang Y, Liu C, Zhao X, Wang Q, Xin Z, Lan Y, Yin C, Yang X.   +8 more
europepmc   +1 more source

Prevalence of Phelan McDermid Syndrome Estimated To Be ~1:7300 Using a Multisource Model

Autism Research, EarlyView.
ABSTRACT Estimating the prevalence of genetic disorders is complicated by many factors including sampling bias and differing methods of estimation. However, establishing the true prevalence of these disorders is critical for understanding disease burden, pharmacoeconomic modeling, and resource allocation for testing and care.
Tess Levy, David Lapidus, Kate Friedman, Paige Siper, Larry Glass, Liza Squires, Mary Hames, Joseph D. Buxbaum, Genetic Testing Consortium, Brooklynn Gasser, Meghan Towne, Behrang Mahjani, Seulgi Jung, Stuart Schwartz, Kai Lee Yap, Mindy Li, Avinash V. Dharmadhikari, Gordana Raca, Dolores B. Estrine, Stefanie Biller, Amanda Singleton, Sarah Poll, Alexander Kolevzon   +22 more
wiley   +1 more source

Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP? [PDF]

J Acquir Immune Defic Syndr
D'Angelo AB, Patel VV, Carrico AW, Grov C.   +3 more
europepmc   +1 more source

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

In Vitro Fertilization Utilization Rates and Outcomes in States With and Without Insurance Coverage Mandates for Male Infertility Care. [PDF]

Urology
Khoei AA, Yan P, Dunn RL, Suh D, Weiss MS, Black K, Marsh EE, Norton EC, Dalton VK, Dupree JM.   +9 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Vision Impairment, Insurance Coverage, and Out-of-Pocket Spending.

JAMA Netw Open
Sultana MS, McInerney M, Boudreaux M, Yu F, Coleman AL, Lipton B.   +5 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source